Posted On: 11/02/2014 9:55:06 PM
Post# of 273318
Endocyte Inc (ECYT) 5.99 $ECYT
Endocyte Announces Third Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Wednesday, Nov. 5, at 4:30 p.m. EST to discuss its third quarter 2014 financial results and provide an operational update.
ECYT: 5.99 (-0.23)
Equities Updates on Pharma Industry - Mylan, Horizon Pharma, Hospira, VIVUS, and Endocyte
PR Newswire - Tue Oct 21, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), VIVUS Inc. (NASDAQ: VVUS), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, October 20, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,399.67, up 0.12% and the NASDAQ Composite closed at 4,316.07, up 1.35%. The S&P 500 finished the session 0.91% higher at 1,904.01. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 716.35, up 1.20%, with the index gaining 11.53% on YTD basis. Register for your complimentary reports on these five stocks at:
ECYT: 5.99 (-0.23), VVUS: 3.39 (+0.03), HZNP: 12.94 (+0.19), MYL: 53.55 (+1.18), HSP: 53.70 (-0.54)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 82.50 (+0.14), ARQL: 1.15 (-0.02), BMY: 58.19 (-0.79), GSK: 45.49 (+0.35), ONTY: 1.80 (-0.12), ECYT: 5.99 (-0.23), MRK: 57.94 (+0.63), AEZS: 1.12 (+0.06), GALE: 2.05 (-0.16), NVS: 92.69 (+0.74), XLRN: 36.98 (-1.26), KPTI: 41.08 (+1.03)
Commit To Purchase Endocyte At $5, Earn 34.1% Annualized Using Options
StockOptionsChannel.com - Thu Oct 02, 10:29AM CDT
Investors considering a purchase of Endocyte Inc shares, but tentative about paying the going market price of $5.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
ECYT: 5.99 (-0.23)
Nasdaq stocks posting largest percentage decreases
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TTS: 8.61 (+0.20), ECYT: 5.99 (-0.23), PDFS: 12.97 (+0.59), CTCM: 6.36 (+0.10), WRES: 3.46 (+0.06), ADHD: 3.62 (-0.05), RTRX: 9.68 (+0.15), GWGH: 9.07 (+0.01), MTEX: 14.40 (+0.21), ELGX: 11.40 (+0.16), DWSN: 16.99 (+0.16), OTIC: 26.35 (+0.73), THRM: 41.70 (+3.60)
Why Endocyte (ECYT) Stock Is Declining Today
at The Street - Tue Sep 30, 10:44AM CDT
Endocyte (ECYT) shares are down after being downgraded to 'hold' by analysts at Brean Capital.
ECYT: 5.99 (-0.23)
Endocyte's TARGET Interim Data Positive for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:25PM CDT
Endocyte, Inc. (ECYT) announced an encouraging interim update on overall survival (OS) of patients in the phase IIb TARGET study on vintafolide for NSCLC.
LCI: 56.72 (+0.83), ENDP: 66.92 (+0.63), ECYT: 5.99 (-0.23), MRK: 57.94 (+0.63)
Why Endocyte, Inc. Stock Briefly Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 29, 12:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company...
ECYT: 5.99 (-0.23), MRK: 57.94 (+0.63)
Phase 2b TARGET Trial Results Show Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated With Endocyte's Vintafolide
GlobeNewswire - Sat Sep 27, 9:15AM CDT
- Data Presented Today as Late-Breaker at European Society for Medical Oncology (ESMO) 2014 Congress in Madrid -
ECYT: 5.99 (-0.23)
Endocyte (ECYT) Flagged As Strong On High Volume
at The Street - Tue Sep 23, 9:01AM CDT
Trade-Ideas LLC identified Endocyte (ECYT) as a strong on high relative volume candidate
ECYT: 5.99 (-0.23)
Endocyte Announces Late-Breaking Abstract Presentation at the European Society for Medical Oncology (ESMO) Conference
GlobeNewswire - Mon Sep 22, 3:46PM CDT
Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that an oral presentation will be presented at the European Society for Medical Oncology (ESMO) Conference on Saturday, Sept. 27, in Madrid, Spain.
ECYT: 5.99 (-0.23)
Top Swing Trade Ideas for Monday: Cerus, Endocyte, More
at The Street - Mon Sep 15, 9:02AM CDT
Cerus, Endocyte and Galectin Therapeutics are our big swing trades for Monday. So, how should investors buy and sell?
CERS: 4.16 (-0.16), ECYT: 5.99 (-0.23), GALT: 5.42 (-0.03)
Endocyte (ECYT) Showing Signs Of A Dead Cat Bounce Today
at The Street - Fri Sep 12, 9:08AM CDT
Trade-Ideas LLC identified Endocyte (ECYT) as a "dead cat bounce" (down big yesterday but up big today) candidate
ECYT: 5.99 (-0.23)
Strength Seen in Flexion Therapeutics (FLXN): Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 8:46AM CDT
Flexion Therapeutics (FLXN) was a big mover last session, with shares rising nearly 18% on the day.
ENDP: 66.92 (+0.63), LCI: 56.72 (+0.83), ECYT: 5.99 (-0.23), FLXN: 19.59 (-0.31)
Aradigm Corporation (ARDM) Up: Stock Adds 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 8:32AM CDT
Aradigm Corporation (ARDM) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
LCI: 56.72 (+0.83), ECYT: 5.99 (-0.23), ARDM: 7.81 (+0.12), HPTX: 24.30 (-0.13)
Avanir Pharmaceuticals (AVNR) in Focus: Stock Surges 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:37AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares rise more than 14% on the day.
LCI: 56.72 (+0.83), ECYT: 5.99 (-0.23), AVNR: 12.94 (-0.26), HPTX: 24.30 (-0.13)
Endocyte Announces Third Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Wednesday, Nov. 5, at 4:30 p.m. EST to discuss its third quarter 2014 financial results and provide an operational update.
ECYT: 5.99 (-0.23)
Equities Updates on Pharma Industry - Mylan, Horizon Pharma, Hospira, VIVUS, and Endocyte
PR Newswire - Tue Oct 21, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), VIVUS Inc. (NASDAQ: VVUS), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, October 20, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,399.67, up 0.12% and the NASDAQ Composite closed at 4,316.07, up 1.35%. The S&P 500 finished the session 0.91% higher at 1,904.01. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 716.35, up 1.20%, with the index gaining 11.53% on YTD basis. Register for your complimentary reports on these five stocks at:
ECYT: 5.99 (-0.23), VVUS: 3.39 (+0.03), HZNP: 12.94 (+0.19), MYL: 53.55 (+1.18), HSP: 53.70 (-0.54)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 82.50 (+0.14), ARQL: 1.15 (-0.02), BMY: 58.19 (-0.79), GSK: 45.49 (+0.35), ONTY: 1.80 (-0.12), ECYT: 5.99 (-0.23), MRK: 57.94 (+0.63), AEZS: 1.12 (+0.06), GALE: 2.05 (-0.16), NVS: 92.69 (+0.74), XLRN: 36.98 (-1.26), KPTI: 41.08 (+1.03)
Commit To Purchase Endocyte At $5, Earn 34.1% Annualized Using Options
StockOptionsChannel.com - Thu Oct 02, 10:29AM CDT
Investors considering a purchase of Endocyte Inc shares, but tentative about paying the going market price of $5.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
ECYT: 5.99 (-0.23)
Nasdaq stocks posting largest percentage decreases
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TTS: 8.61 (+0.20), ECYT: 5.99 (-0.23), PDFS: 12.97 (+0.59), CTCM: 6.36 (+0.10), WRES: 3.46 (+0.06), ADHD: 3.62 (-0.05), RTRX: 9.68 (+0.15), GWGH: 9.07 (+0.01), MTEX: 14.40 (+0.21), ELGX: 11.40 (+0.16), DWSN: 16.99 (+0.16), OTIC: 26.35 (+0.73), THRM: 41.70 (+3.60)
Why Endocyte (ECYT) Stock Is Declining Today
at The Street - Tue Sep 30, 10:44AM CDT
Endocyte (ECYT) shares are down after being downgraded to 'hold' by analysts at Brean Capital.
ECYT: 5.99 (-0.23)
Endocyte's TARGET Interim Data Positive for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:25PM CDT
Endocyte, Inc. (ECYT) announced an encouraging interim update on overall survival (OS) of patients in the phase IIb TARGET study on vintafolide for NSCLC.
LCI: 56.72 (+0.83), ENDP: 66.92 (+0.63), ECYT: 5.99 (-0.23), MRK: 57.94 (+0.63)
Why Endocyte, Inc. Stock Briefly Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 29, 12:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company...
ECYT: 5.99 (-0.23), MRK: 57.94 (+0.63)
Phase 2b TARGET Trial Results Show Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated With Endocyte's Vintafolide
GlobeNewswire - Sat Sep 27, 9:15AM CDT
- Data Presented Today as Late-Breaker at European Society for Medical Oncology (ESMO) 2014 Congress in Madrid -
ECYT: 5.99 (-0.23)
Endocyte (ECYT) Flagged As Strong On High Volume
at The Street - Tue Sep 23, 9:01AM CDT
Trade-Ideas LLC identified Endocyte (ECYT) as a strong on high relative volume candidate
ECYT: 5.99 (-0.23)
Endocyte Announces Late-Breaking Abstract Presentation at the European Society for Medical Oncology (ESMO) Conference
GlobeNewswire - Mon Sep 22, 3:46PM CDT
Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that an oral presentation will be presented at the European Society for Medical Oncology (ESMO) Conference on Saturday, Sept. 27, in Madrid, Spain.
ECYT: 5.99 (-0.23)
Top Swing Trade Ideas for Monday: Cerus, Endocyte, More
at The Street - Mon Sep 15, 9:02AM CDT
Cerus, Endocyte and Galectin Therapeutics are our big swing trades for Monday. So, how should investors buy and sell?
CERS: 4.16 (-0.16), ECYT: 5.99 (-0.23), GALT: 5.42 (-0.03)
Endocyte (ECYT) Showing Signs Of A Dead Cat Bounce Today
at The Street - Fri Sep 12, 9:08AM CDT
Trade-Ideas LLC identified Endocyte (ECYT) as a "dead cat bounce" (down big yesterday but up big today) candidate
ECYT: 5.99 (-0.23)
Strength Seen in Flexion Therapeutics (FLXN): Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 8:46AM CDT
Flexion Therapeutics (FLXN) was a big mover last session, with shares rising nearly 18% on the day.
ENDP: 66.92 (+0.63), LCI: 56.72 (+0.83), ECYT: 5.99 (-0.23), FLXN: 19.59 (-0.31)
Aradigm Corporation (ARDM) Up: Stock Adds 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 8:32AM CDT
Aradigm Corporation (ARDM) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
LCI: 56.72 (+0.83), ECYT: 5.99 (-0.23), ARDM: 7.81 (+0.12), HPTX: 24.30 (-0.13)
Avanir Pharmaceuticals (AVNR) in Focus: Stock Surges 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:37AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares rise more than 14% on the day.
LCI: 56.72 (+0.83), ECYT: 5.99 (-0.23), AVNR: 12.94 (-0.26), HPTX: 24.30 (-0.13)
(0)
(0)
